Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

(E/Z)-Droloxifene is a mixture of (E)-droloxifene, a selective estrogen receptor modulator (SERM), and (Z)-droloxifene.1 (E)-Droloxifene binds to the estrogen receptor (ER) in rabbit uterine homogenates (IC50 = 24 nM in a radioligand binding assay), increases uterine weight in immature rats, and reduces estradiol-induced increases in uterine weight in juvenile rats.1,2,3 It also inhibits 17β-estradiol-stimulated growth of MCF-7, ZR-75-1, and T47D human breast cancer cells in a concentration-dependent manner.4 (Z)-Droloxifene binds weakly to ERs and has no estrogenic or antiestrogenic activity.5
WARNING This product is not for human or veterinary use.
1. Selective oestrogen receptor modulators/new antioestrogens: A clinical perspective. Cancer Treat. Rev. 30(8), 695-706 (2004).
2. In vivo and in vitro antiestrogenic action of 3-
3. Preclinical data for droloxifene. Cancer Lett. 84(2), 101-116 (1994).
4. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers. Jpn. J. Pharmacol. 63(1), 27-34 (1993).
5. Pharmacological activities of droloxifene isomers. Anticancer Res. 8(6), 1271-1274 (1988).